You are here

  • Home
  • Archive
  • Volume 8, Issue 3
  • Review: ipratropium is not more effective than β2 agonists for acute exacerbations of chronic obstructive pulmonary disease

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: ipratropium is not more effective than β2 agonists for acute exacerbations of chronic obstructive pulmonary disease

https://doi.org/10.1136/ebm.8.3.74

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) Cochrane Database Syst Rev , CD003900; McCrory DC, Brown CD.. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease.. ;. (4). :.

    
 
 QUESTION: In patients with acute exacerbations of chronic obstructive pulmonary disease (COPD), are anticholinergic agents more effective than placebo or β2 agonists?

    Data sources

    Studies were identified by searching Medline, EMBASE/Excerpta Medica, CINAHL, and the Cochrane COPD Trials Register, using the terms bronchodilator, ipratropium, and oxitropium; and by scanning bibliographies of relevant studies.

    Study selection

    Studies were selected if they were randomised controlled trials (RCTs) comparing anticholinergic agents (ipratropium or oxitropium bromide, given by inhalation by nebuliser or metered dose inhaler) with an appropriate control (eg, placebo, other bronchodilating agents, or combination therapies) and assessed adults with a diagnosis of COPD having symptoms of acute exacerbation of COPD. Studies of patients with acute asthma or those receiving ventilation were excluded.

    Data extraction

    Data were extracted on study quality and methods, participants, interventions, …

    View Full Text

    Footnotes

    • Source of funding: Agency for Health Care Research and Quality.

    • For correspondence: Dr D McCrory, Duke University Medical Center, Durham, NC, USA.douglas.mccrory{at}duke.edu

    • Abstract and commentary also appear in ACP Journal Club.